Fig. 3.

LMO3 increases glucose clearance and insulin sensitivity in eWAT during obesity. All mice were kept on HFD for 12 weeks and received rAAV-YFP or rAAV-Lmo3 injections into eWAT at week 2 of HFD and were examined 10 weeks later. A Experimental scheme for murine studies. B Lmo3 mRNA expression in eWAT (n = 5/group). C Confocal immunofluorescence of eWAT. Scale bar = 50 μm. D Body weight gain over time (n = 8/group). E eWAT fat pad weight after 10 weeks of HFD (n = 6/group). F Serum free fatty acid levels (n = 10/group). G Serum adiponectin levels (n = 10/group). H Oral glucose tolerance test and corresponding blood glucose and insulin levels in obese mice (n = 6/group). I Area under the curve (AUC) for oGTT (n = 6/group). J Basal blood glucose levels in obese mice (n = 6/group). K Basal blood insulin levels in obese mice (n = 6/group). L Insulin tolerance test and corresponding blood glucose levels in obese mice (n = 6/group). M Area under the curve (AUC) for ITT (n = 6/group). *p < 0.05, **p < 0.01, ***p < 0.001, ns, not significant